Use of SAXENDA for this indication is supported by a 56-week double-blind, placebo-controlled clinical trial in 251 pediatric patients aged 12 to 17 years, a pharmacokinetic study in pediatric patients, and studies in adults with obesity [see Clinical Pharmacology (12.3), Clinical Studies (14.1, 14.2)]
For example, theyre contraindicated for women who are pregnant, those with a hypersensitivity to the drug, those with necrotizing pancreatitis, and patients with a family history of thyroid cancer
Additionally, there is a potential risk of thyroid tumors, including medullary thyroid carcinoma
Personalized Care: Remember that every individual is different, and what works for one person may not work for another
Reduces Appetite Naturally: Works with your body's hunger signals to curb cravings without willpower alone
Norgaard RA, Bhatt DK, Jarvinen E, et al